Blog
RSS FeedPosted by Michael Wonder on 01 Aug 2025
ICER to assess therapies for IgA nephropathy
31 July 2025 - Report will be subject of CTAF meeting in February 2026; draft scoping document open to public ...
Posted by Michael Wonder on 23 Jul 2025
ICER releases draft evidence report on treatment for non-cystic fibrosis bronchiectasis
23 July 2025 - Public comment period now open until 19 August 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 18 Jul 2025
ICER publishes evidence report on treatments for spinal muscular atrophy
17 July 2025 - There are many remaining uncertainties around the best management of spinal muscular atrophy; ICER estimates that ...
Posted by Michael Wonder on 15 Jul 2025
ICER publishes final evidence report on treatment for secondary progressive multiple sclerosis
15 July 2025 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 29 May 2025
ICER publishes evidence report on treatment for secondary progressive multiple sclerosis
29 May 2025 - There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve ...
Posted by Michael Wonder on 27 May 2025
ICER releases draft evidence report on treatments for spinal muscular atrophy
27 May 2025 - Public comment period now open until 24 June 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 21 May 2025
ICER to assess treatment for smoking cessation
20 May 2025 - Report will be subject of Midwest CEPAC meeting in January 2026; draft scoping document open to ...
Posted by Michael Wonder on 19 May 2025
ICER publishes protocol for first annual launch price and access report
19 May 2025 - Report to be issued in October 2025. ...
Posted by Michael Wonder on 16 May 2025
ICER publishes final evidence report on treatment for retinitis pigmentosa
15 May 2025 - Independent appraisal committee voted that current evidence is adequate to demonstrate a net health benefit of ...
Posted by Michael Wonder on 29 Apr 2025
Institute for Clinical and Economic Review to assess treatments for obesity management
29 April 2025 - Report will be subject of New England CEPAC meeting in November 2025; draft scoping document open ...
Posted by Michael Wonder on 15 Apr 2025
ICER releases draft evidence report on treatment for secondary progressive multiple sclerosis
15 April 2025 - Public comment period now open until 13 May 2025; Requests to make oral comment during public ...
Posted by Michael Wonder on 10 Apr 2025
ICER releases obesity medications white paper examining strategies to ensure affordable access
9 April 2025 - Paper analyses policy reforms and market actions to achieve affordable and equitable access for GLP-1 obesity ...
Posted by Michael Wonder on 01 Apr 2025
ICER publishes final evidence report on treatment for acute pain
31 March 2025 - Independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic ...
Posted by Michael Wonder on 27 Mar 2025
ICER publishes evidence report on treatment for retinitis pigmentosa
26 March 2025 - There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that ...
Posted by Michael Wonder on 20 Mar 2025
Health Economics Methods Advisory Group selects first area for study: assessing treatment benefits appropriate to consider in HTA decision-making
18 March 2025 - The US based ICER, England’s NICE and Canada’s Drug Agency have selected the first research topic ...